Drugs in ATC Class B02BA

Up to Top Level ATC Classes

Up to B - Blood and blood forming organs

Up to B02 - ANTIHEMORRHAGICS

Up to B02B - VITAMIN K AND OTHER HEMOSTATICS

Drugs in ATC Class: B02BA - Vitamin K

Tradename	Generic Name
MENADIONE	menadione

Market Dynamics and Patent Landscape for ATC Class B02BA (Vitamin K): Exclusivity, Patent Risk, and Competitive Positioning

Last updated: June 10, 2026

ATC Class B02BA (Vitamin K) is a mature, largely off-patent small-molecule space with limited remaining blockbuster-grade IP. Commercial risk is dominated by (1) whether specific vitamin K products have non-expired formulation, manufacturing, or method-of-use patents, and (2) how quickly generics and interchangeably substitutable products can enter once regulatory exclusivity and any Orange Book-listed patents clear. In practice, the market dynamics center on supply continuity, drug form (oral vs injectable vs pediatric), and procurement contracting more than on near-term exclusivity cliffs.

This write-up maps the patent and exclusivity mechanics that typically govern vitamin K products in the US (Orange Book, patents and exclusivity) and Europe (national/regional patent enforcement plus SPC regimes where applicable), then translates them into generic and biosimilar entry scenarios. It also provides an operator-facing checklist for identifying the actual “protecting” patents per marketed vitamin K product, since the class label B02BA spans multiple actives and product presentations.

Which vitamin K products fall under ATC B02BA and how do they drive revenue exposure?

ATC B02BA is commonly used to cover vitamin K therapeutics used to prevent or treat vitamin K deficiency states and bleeding related to impaired coagulation, with the core active ingredients typically including:

• Vitamin K1 (phylloquinone)
• Vitamin K3 (menadione; in some markets also used historically, often with more restricted safety profiles and different regulatory posture)

Market exposure depends on the specific marketed presentations because contracting and clinician preference are formulation- and logistics-dependent:

• Injectable vs oral: hospital procurement favors injectable continuity, especially for reversal and deficiency settings.
• Pediatric and high-concentration formulations: tend to attract formulation and process IP (if present) and tighter manufacturing controls.
• Combination products and supportive co-packaging: can carry additional IP around dosing regimens or excipient systems.

Featured snippet answer: ATC B02BA market dynamics are driven by product presentation (injectable vs oral), tender-driven procurement, and the presence of any remaining Orange Book-listed formulation/manufacturing patents tied to specific vitamin K strengths and dosage forms, not by broad class-level exclusivity.

How do hospital-use vs outpatient-use patterns change the patent value chain?

• Hospital injectable demand increases sensitivity to manufacturing interruptions. Even without enforceable patents, market incumbency can persist through supply reliability, lot-release consistency, and clinician familiarity.
• Outpatient vitamin K repletion tends to clear faster after loss of regulatory exclusivity because pharmacy-level substitution reduces value of minor formulation differentiation.

What patents protect vitamin K products in practice: drug substance, formulation, method-of-use, or manufacturing?

For vitamin K products, the legally relevant question is not whether “vitamin K” is patented, but whether the exact marketed product is covered by:

1. US Orange Book-listed patents for the drug product
2. non-listed patent families that could be asserted despite Orange Book (process, formulation, or medical use)
3. regulatory exclusivity (new chemical entity, new formulation, pediatric, orphan, etc., as applicable)
4. Supplementary Protection Certificates (SPCs) in EU jurisdictions where they apply

Featured snippet answer: Vitamin K products are typically protected, where protection remains, by formulation and manufacturing patents tied to specific strengths, compositions, or sterilization and stability processes. Broad drug-substance patents for vitamin K actives are largely historical and often expired.

Patent categories that matter for ATC B02BA

Formulation patents (most common “remaining” IP)

• Solubility and stability systems for injectable vitamin K
• Excipient blends that control pH, antioxidant content, and chemical degradation
• Packaging-specific stability claims (light/oxygen protection, overwraps, container closures)

Manufacturing and process patents

• Sterile filtration, aseptic processing steps
• Filling line parameters that avoid degradation
• Scale-up and lot control parameters
• Stability-indicating analytics method claims (sometimes asserted)

Method-of-use patents

• Dosing regimens, route selection (IV vs IM), or special populations (pediatrics, neonates, liver disease)
• Clinical use tied to bleeding risk management protocols

Drug substance patents

• Often expired for generic-usable actives like vitamin K1

When does vitamin K lose exclusivity and how do you calculate the generic entry window?

Generic entry timing in the US depends on:

• Patent expiration (for Orange Book patents listed for the drug product)
• Regulatory exclusivity periods that can bar approval even after patent expiration
• The Hatch-Waxman mechanism for ANDA applicants using Paragraph IV

Featured snippet answer: The earliest generic entry is typically constrained by the latest-expiring US Orange Book patent tied to the specific vitamin K NDA or ANDA reference listed drug (RLD). Regulatory exclusivity can add a second floor even if patents expire earlier.

Generic timing logic (operator-ready)

For each marketed vitamin K RLD:

1. Identify Orange Book patents by submission type: composition/formulation, method of use, and manufacturing.
2. Determine patent expiration dates (and any terminal disclaimers or patent term adjustments).
3. Check for pediatric exclusivity extensions (where applicable).
4. Determine whether an ANDA can be approved before patent expiration based on:
   • Carve-outs from method-of-use claims
   • Design-around formulations that avoid literal infringement and allow “non-infringement” positions

What is the Orange Book status of vitamin K products and which patents are listed?

No single Orange Book status exists for “vitamin K” as a class. The Orange Book is drug-product specific. For a working patent landscape, the needed unit of analysis is:

• The NDA (or ANDA RLD) for each vitamin K strength and dosage form
• The list of US patents with expiration dates and claim types

Featured snippet answer: Orange Book listings define enforceable patent risk for US generic entry. Class-level vitamin K IP does not substitute for drug-product specific Orange Book analysis.

How to interpret Orange Book lists for B02BA

Orange Book lists usually show:

• Patent number
• Expiration date
• Patent type (drug substance, drug product, use)
• Listing NDA/label association

In mature classes like vitamin K, patent lists can be thin or largely expired, leaving only limited remaining formulation or process patents for specific strengths.

How many patents cover vitamin K and what jurisdictions carry enforceable risk?

Coverage is fragmented:

• US: determined by Orange Book plus separate enforceable patent families
• Europe: enforcement via national courts and validity via European and national filings; SPC can extend drug product protection if a qualifying marketing authorization and base patent exist
• Other markets: national patent term and local marketing exclusivity rules apply

Featured snippet answer: Expect the effective “IP perimeter” for vitamin K to be small in the US and EU compared with newer therapeutics. Risk usually concentrates in specific strengths, sterile injectable presentations, and any late-cycle formulation patents.

Where IP risk clusters in vitamin K

• Sterile injectable vitamin K: stability and process patents, plus packaging claims
• Pediatric formulations: excipient and dosing system claims
• High-concentration strengths: solubility and viscosity controlled formulations

What generic entry risks exist for vitamin K and what could trigger a Paragraph IV filing?

For a Paragraph IV ANDA, risk materializes when:

• There is an Orange Book patent still in force for the RLD
• The ANDA filer believes it can either:
  • design around the claims (non-infringement),
  • invalidate the claims (invalidity), or
  • argue unenforceability

Featured snippet answer: Paragraph IV risk for vitamin K depends on whether the RLD has any unexpired Orange Book patents. In a mature class, many filings may be “Section viii only” without Paragraph IV exposure once patents clear.

How supply constraints can outweigh patent barriers

Even when patents clear, incumbents can retain market share due to:

• supply chain capacity
• regulatory lot release performance
• procurement contracts and substitution barriers

What patent litigation affects vitamin K and how do settlements shape market entry?

In mature, low-blockbuster classes, litigation, if any, is usually narrow and product-specific:

• disputes around sterile injectable manufacturing
• formulation equivalence and stability
• method-of-use claims, where still present

Settlement agreements typically do one of two things:

• agreed “at-risk” launch dates for generic entry
• licensing with royalties or supply agreements (less common in low-margin commodity-like spaces)

Featured snippet answer: Litigation and settlements in vitamin K are product-specific and tend to be limited in scope; the dominant market lever remains whether any enforceable patents remain for the exact dosage form and strength.

How do formulation and manufacturing patents affect generic bioequivalence and regulatory approval?

For small molecules, bioequivalence is usually straightforward for oral forms, but injectable products can bring extra complexity:

• stability and degradation profiles
• excipient systems impacting assay, impurities, and shelf life
• sterilization and aseptic processing reproducibility

Featured snippet answer: Even when pharmacokinetic bioequivalence is easy to demonstrate, formulation and manufacturing patent protection can still block approval or delay launch through design-around requirements or litigation.

Common design-around vectors

• Change excipient ratios while maintaining equivalence and stability
• Use alternative sterilization or filtration process parameters that avoid infringement
• Modify container closure systems if permitted without destabilizing the product

How does vitamin K market competition compare across regions (US vs EU vs key emerging markets)?

US

• The Orange Book governs patent listing and Hatch-Waxman leverage.
• Regulatory exclusivity can create an additional delay floor.

EU

• Enforcement is national; SPC can matter if a qualifying patent/SPC exists.
• Substitution and procurement rules differ by member state, affecting speed of generic adoption.

Emerging markets

• Patent enforcement strength varies widely.
• Market entry may track regulatory clearance speed more than legal clearance.

Featured snippet answer: Region-to-region timing differences mostly reflect how strongly patents and SPCs are enforced and how substitution is handled in procurement channels.

What regulatory pathways are used for generic vitamin K and how does exclusivity impact approvals?

Generic vitamin K products generally use:

• ANDA in the US where an RLD exists
• national generic pathways in EU and local pathways elsewhere

Exclusivity impact is governed by:

• patent expiration and any still-in-force Orange Book patents
• product-specific exclusivity periods

Featured snippet answer: If the RLD is fully off-patent and no regulatory exclusivity remains, generic approval can proceed on bioequivalence and quality documentation, with commercial delay driven more by supply and tendering than by legal barriers.

Key market mechanics: pricing, contracting, and how IP translates to commercial outcomes

In B02BA-like vitamin classes, IP value is often constrained by:

• commoditization of the active ingredient
• substitution at pharmacy level or in formularies once equivalence is established
• procurement-driven pricing pressure

IP still matters when it controls:

• availability of a key presentation (especially injectable)
• shelf-life and supply reliability
• pediatric-ready formats

Featured snippet answer: Patent estates for vitamin K typically translate into limited-duration commercial protection for specific presentations. Once cleared, pricing convergence accelerates quickly.

Key Takeaways

• ATC B02BA vitamin K is a mature category where active-substance patents are often expired; remaining protection, when present, is usually formulation and manufacturing, tied to specific strengths and dosage forms.
• US generic entry timing is determined product-by-product by Orange Book listed patents and any applicable regulatory exclusivity; class-level “vitamin K” IP is not a reliable proxy.
• Market dynamics are procurement and supply-driven. Even after legal clearance, incumbent advantage can persist via manufacturing reliability and contracting.
• Litigation risk is typically narrow and product-specific. Paragraph IV exposure exists only where unexpired Orange Book patents remain for the exact RLD.

FAQs

1) Do vitamin K formulations require Paragraph IV challenges to enter the market in the US?
Usually no if the RLD is off-patent and has no unexpired Orange Book patents; otherwise Paragraph IV may be required depending on the remaining listed patent set.

2) What claim types most frequently delay generics for injectable vitamin K?
Formulation and manufacturing/process claims related to stability, excipient systems, and sterile manufacturing are the most common remaining IP levers.

3) Can a generic vitamin K oral product launch before injectable equivalents once patents expire?
Yes, if patents are tied to specific dosage forms or strengths. Each presentation’s Orange Book and exclusivity profile determines its launch timeline.

4) How do settlements in low-value patent estates typically affect launch timing for vitamin K generics?
Settlements, when they occur, tend to set narrow launch dates or provide limited licensing terms rather than broad long-term market protection.

5) Does SPC in Europe materially extend protection for vitamin K products?
Only if the product qualifies under SPC rules linked to a qualifying base patent and marketing authorization. Protection impact is presentation- and dossier-specific.

References

No sources were provided in the prompt, and no reliable, product-specific Orange Book, patent, or litigation datasets were included in the input; therefore, no citations can be listed.